These sales were conducted as part of a pre-established Rule 10b5-1 trading plan, which allows company insiders to set up a predetermined plan for selling stocks. The transactions were made to cover tax withholding obligations related to the vesting of restricted stock units. Following these sales, Rolph holds 178,337 shares in the company. The company maintains a strong financial position with a current ratio of 17.25 and more cash than debt on its balance sheet. InvestingPro subscribers can access 8 additional key insights about Akero's financial health and market performance. The company maintains a strong financial position with a current ratio of 17.25 and more cash than debt on its balance sheet. InvestingPro subscribers can access 8 additional key insights about Akero's financial health and market performance.
These sales were conducted as part of a pre-established Rule 10b5-1 trading plan, which allows company insiders to set up a predetermined plan for selling stocks. The transactions were made to cover tax withholding obligations related to the vesting of restricted stock units. Following these sales, Rolph holds 178,337 shares in the company.
In other recent news, Keros Therapeutics has voluntarily paused dosing in certain arms of its Phase 2 TROPOS Trial following the identification of unexpected cases of pericardial effusion among participants. Dosing at the 1.5 mg/kg level continues as the company works with the FDA and other regulatory authorities to understand these unanticipated findings. Keros plans to present topline data from all treatment arms of the TROPOS trial in the second quarter of 2025.
Meanwhile, Akero Therapeutics (NASDAQ:AKRO) has been making significant strides in its clinical trials. The company reported positive outcomes from its Phase 2b HARMONY study, showing that efruxifermin (EFX) treatment led to regression of liver fibrosis in over 40% of participants. Additionally, Akero has initiated all three Phase 3 trials of EFX, with the first patient already dosed in the SYNCHRONY Outcomes study.
Analysts have taken note of these developments, with Citi initiating coverage on Akero with a Buy rating, citing the potential of efruxifermin to lead in the treatment of metabolic dysfunction-associated steatohepatitis (MASH). H.C. Wainwright has also maintained a Buy rating for Akero, as the company progresses with its Phase 3 trials. Investors are awaiting the Week 96 data release from the ongoing Phase 2b SYMMETRY study, expected in the first quarter of 2025, which will provide insights into the long-term effects of EFX on MASH patients.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.